Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enablex cognition study

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Novartis' overactive bladder agent Enablex (darifenacin) did not impair cognition in a study in 129 elderly patients (aged 65 and up) who did not have clinical dementia. "While the study was powered to detect an improvement in cognitive function, [investigators] noted that Enablex had no effect on the three primary cognitive endpoints (memory scanning sensitivity, speed of choice reaction time, and word recognition sensitivity) at any dose," Novartis says Feb. 24. The majority of OAB patients are over 65 and therefore more susceptible to cognitive disorders as well as drug-induced cognitive impairment, the firm notes...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002820

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel